Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who have given written agreement to take part.
- People who have been diagnosed with a heart condition called Hypertrophic Obstructive Cardiomyopathy (HOCM), where the heart muscle is abnormally thick (at least 15mm) and blood flow out of the heart is partially blocked, confirmed by standard diagnostic tests.
- People who have symptoms that may suggest the heart muscle is not getting enough blood supply, such as chest pain or shortness of breath during activity, and for whom a specific type of heart scan called a Rubidium PET scan has been recommended by their doctor.
- People for whom a medication called Mavacamten has been recommended as part of their normal clinical care, in line with established treatment guidelines — this medication is part of their regular treatment and is not being provided or influenced by this study.
- People who have already had a PET-CT scan for clinical reasons within the past 18 months, where the results were reported as abnormal.
Who may not be able to join:
- People who have been found to have significant blockages in the main heart arteries (more than 50% narrowing), identified through a standard clinical heart artery scan or procedure carried out as part of their usual care before any approach to join this study.
- People for whom Mavacamten is not considered safe, including those whose heart pumping function is below a certain level (left ventricular ejection fraction under 55%), or those who have had an allergic or sensitivity reaction to this medication.
- People who are pregnant or breastfeeding, as the PET-CT scan is not suitable in these circumstances.
- People with severe claustrophobia (strong fear of enclosed spaces) that would prevent them from undergoing the scan.
- People whose body size exceeds the physical limits of the scanning equipment.
- People who have another medical condition that, in the opinion of the treating doctor overseeing the trial, could put them at greater risk from taking part, or that would make it unlikely they could complete the study requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andrew Crean, BSc BM MRCP FRCR MPhil MPH, University of Manchester
Phone: +447413060202
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Myocardial Ischaemia:; Change in Myocardial Ischaemia:; Change in Myocardial Ischaemia:
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.